Ginkgo Bioworks Cash Flow Statement
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks free cash flow
In fiscal 2025, Ginkgo Bioworks generated -$171.1 million of operating cash flow and spent $7.7 million on capital expenditures. That left free cash flow of -$178.7 million, a free-cash-flow margin of -105.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -312.76M | -547.03M | -892.87M | -2.11B | -1.84B | -126.72M | -119.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 58.99M | 63.02M | 70.51M | 42.55M | 29.08M | 13.86M | 10.76M |
| Stock-Based Compensation | 81.55M | 112.34M | 229.88M | 1.93B | 1.61B | 476.00K | 771.00K |
| Change in Working Capital | -42.10M | -58.51M | 23.44M | -596.00K | -131.07M | -40.72M | -327.00K |
| Operating Cash Flow | -171.06M | -319.58M | -295.50M | -252.20M | -253.82M | -135.83M | -44.66M |
| Capital Expenditures | -7.67M | -62.54M | -40.80M | -52.27M | -56.52M | -57.82M | -22.22M |
| Investing Cash Flow | -240.29M | -62.24M | -80.69M | -67.39M | -73.26M | -67.12M | -74.60M |
| Share Repurchases | — | — | 0 | 0 | -25.00M | 0 | -408.00K |
| Financing Cash Flow | 17.77M | -1.74M | -3.22M | 95.34M | 1.53B | 90.32M | 410.38M |
| Net Change in Cash | -393.37M | -383.84M | -380.00M | -223.35M | 1.21B | -112.63M | 291.12M |
| Free Cash Flow | -178.72M | -382.13M | -336.30M | -304.47M | -310.34M | -193.65M | -66.88M |
This table shows 7 annual periods of Ginkgo Bioworks's cash flow statement, from FY 2025 back to FY 2019, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a cash flow statement?